地西他滨单药治疗老年急性髓细胞白血病的临床观察

Clinical observation of decitabine in treating elderly acute myeloid leukemia

目的:探讨地西他滨单药5天方案治疗老年急性髓细胞白血病(AML)的临床疗效及安全性。方法:17例老年AML患者,应用地西他滨20mg/(m2·d)×5d方案,分析其临床疗效及不良反应。结果:17例患者中,完全缓解6例(35.3%),部分缓解5例(29.4%),总有效率64.7%;Ⅲ-Ⅳ度血液学毒副反应15例(88.2%),1例患者因化疗相关死亡。结论:地西他滨单药治疗老年AML有确切的疗效,能够改善患者生存质量,延长治疗时间,不良反应对于老年患者可以耐受。

Objective：To explore the clinical efficacy and safety of decitabine 5-day program treatment for acute myeloid 1 eukemia（AML）.Method：We collected clinical data of 17 patients with AML,who were received the therapeutic regimen with decitabine 5-day program（20mg·m-2·d×5d）.The clinical efficacy and adverse reactions were evaluated.Result：Among the 17 patients,6 cases（35.3%）achieved complete remission,5cases（29.4%）achieved partial remission,with the total remission rate of 64.7%.GradeⅢ-Ⅳ bone marrow depression occurred in 15 cases with incidence rate of 88.2%,1 patient died due to chemotherapy.Conclusion：Decitabine is effective in treating elderly AML,and patients can tolerate the adverse effect in chemotherapy.